Showing 6131-6140 of 8850 results for "".
- ArteFill Changes Name to Bellafillhttps://practicaldermatology.com/news/artefill-changes-name-to-bellafill/2459051/Suneva Medical, Inc.’s ArteFill dermal filler has been rebranded as Bellafill in the US. "We feel that the brand Bellafill better embodies the transformational outcomes this unique product can provide to our customers and th
- FDA Approves Valeant's Onexton Gel for the Treatment of Acne Vulgarishttps://practicaldermatology.com/news/fda-approves-valeants-onexton-gel-for-the-treatment-of-acne-vulgaris/2459053/The FDA approved Valeant Pharmaceuticals International, Inc.’s Onexton Gel (clindamycin phosphate and benzoyl peroxide) 1.2%/3.75% for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. "We are very pleased that the FDA has approved this new d
- Galderma Partners with AARS in Support of CDC's "Get Smart About Antibiotics Week"https://practicaldermatology.com/news/20141121-galderma_partners_with_aars_in_support_of_cdcs_get_smart_about_antibiotics_week/2459055/Galderma Laboratories, L.P. joined the American Acne and Rosacea Society (AARS) and the Centers for Disease Control and Prevention's (CDC) Get Smart About Antibiotics Week 2014 (November 17 – 23). AARS and Galderma Laboratories, the first dermatology partner to join with AARS on the initiative, are
- FDA Grants Breakthrough Status to AD Drug Dupilumabhttps://practicaldermatology.com/news/20141121-fda_grants_breakthrough_status_to_ad_drug_dupilumab/2459056/The FDA has awarded breakthrough therapy designation to the investigational drug dupilumab for the treatment of adults with moderate-to-severe atopic dermatitis (AD) who had an insufficient response to and/or who are not suitable for topical prescription therapy. Dupilumab blocks IL-4 and IL-13, whi
- Gabrielle Rios, Founder of TruInject, Wins Stevie Award for Startupshttps://practicaldermatology.com/news/20141119-gabrielle_rios_founder_of_truinject_wins_stevie_award_for_startups/2459058/Gabrielle Rios, chief executive officer of TruInject Medical Corporation, received the Bronze Award at the 2014 Stevie Awards for Women in Business. The award was presented in the category of Startup of the Year. The Stevie® Awards for Women in Business honors women executives, entrepreneurs, a
- Valeant Comments On Allergan Announcementhttps://practicaldermatology.com/news/20141117-valeant_comments_on_allergan_announcement/2459060/Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock. "We have seen the annou
- Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenuehttps://practicaldermatology.com/news/20141117-actavis_to_acquire_allergan_to_create_top_10_global_growth_pharmaceutical_company_with_23_billion_in_revenue/2459062/Actavis plc (NYSE: ACT) and Allergan, Inc. (NYSE: AGN) today announced that they have entered into a definitive agreement under which Actavis will acquire Allergan for a combination of $129.22 in cash and 0.3683 Actavis shares for each share of Allergan common stock. Based on the closing price of A
- Oculus Innovative Sciences Commercializes Microcyn-Based Solution and Hydrogel for Treatment of Mild-to-Moderate Acne in Europehttps://practicaldermatology.com/news/20141113-oculus_innovative_sciences_commercializes_microcyn-based____solution_and_hydrogel_for_treatment_of_mild-to-moderate_acne_in_europe/2459068/Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in 37 countries, today announced the European commercialization of Microcyn(R)-based GramaDerm(TM) Solution a
- ASDS Elects New Officers and Board Membershttps://practicaldermatology.com/news/20141112-asds_elects_new_officers_and_board_members/2459071/The American Society for Dermatologic Surgery (ASDS) announced the election of Tom Rohrer,
- Dr. Mary Lupo Joins Aquavit Pharmaceuticals' Scientific Advisory Boardhttps://practicaldermatology.com/news/20141106-dr_mary_lupo_joins_aquavit_pharmaceuticals_scientific_advisory_board/2459072/Mary Lupo, MD, FAAD has joined the US Scientific Advisory Board of Aquavit Pharmaceuticals. Dr. Lupo is a board-certified dermatologist who is internationally recognized for non-surgical skin rejuvenation. In 1984, she opened